Appendix D 
NON-TECHNICAL ABSTRACT : 
Autologous bone marrow transplantation is a technique which 
makes safe the very high doses of chemotherapy and radiation which 
are required to eradicate some populations of leukemia cells. The 
marrow is removed from the hip bones of the patient at the time of 
remission and stored induced by conventional dose chemotherapy, and 
re-infused into the patient after intensive therapy in order to 
restore marrow function. Peripheral blood will also be used for 
the restoration of hematopoietic function following bone marrow 
transplantation. We will compare peripheral blood with marrow with 
respect to their ability to promote hematopoietic recovery. It is 
impossible to determine if relapse arises from residual leukemia 
cells infused with the autologous stem cells or if residual 
leukemia cells present in systemic circulation after intensive 
therapy contribute to the relapse. Molecules called "marking 
vectors" can be used to resolve this question, and to compare the 
relative contribution of the peripheral blood with the marrow which 
contribute to hematopoietic recovery of normal cells. A portion of 
the bone marrow and peripheral blood cells stored from patients 
will be incubated with the marking vector. This vector will 
introduce a new genetic marker into these leukemia cells. If the 
leukemia cells appearing at relapse contain the marker, then the 
relapse arose from cells infused with the autologous 
transplantation. If this is the case, more thorough procedures 
must be undertaken to cleanse the marrow of leukemia cells. If no 
markers appear at the time of relapse in the leukemia cells, then 
the relapse arose from the systemic circulation. In this case, the 
therapy used to eradicate leukemia from the circulation before 
transplant must be intensified. In this study, marking molecules, 
called LNL6 and GINa , will be used to tag the leukemic blast cells 
of each patient infused to regenerate marrow function after 
intensive therapy. The vectors LNL6 and GINa will also be used to 
tag the normal marrow and peripheral blood cells respectively. The 
results of this study will be used to improve the therapy given to 
patients. It is not designed to benefit the patients themselves. 
[880] 
Recombinant DNA Research, Volume 15 
